Home - Products - Angiogenesis - EGFR - Lidocaine Hydrochloride hydrate

Lidocaine Hydrochloride hydrate

CAS No. 6108-05-0

Lidocaine Hydrochloride hydrate( —— )

Catalog No. M15297 CAS No. 6108-05-0

Lidocaine, an amide local anesthetic, has anti-inflammatory properties in vitro and in vivo.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 28 In Stock
50MG 28 In Stock
100MG 39 In Stock
200MG Get Quote In Stock
500MG 89 In Stock
1G 132 In Stock

Biological Information

  • Product Name
    Lidocaine Hydrochloride hydrate
  • Note
    Research use only, not for human use.
  • Brief Description
    Lidocaine, an amide local anesthetic, has anti-inflammatory properties in vitro and in vivo.
  • Description
    Lidocaine, an amide local anesthetic, has anti-inflammatory properties in vitro and in vivo, possibly due to an attenuation of pro-inflammatory cytokines, intracellular adhesion molecule-1 (ICAM-1), and reduction of neutrophils influx.(In Vitro):Lidocaine (Lignocaine) (10 nM; 48 hours) decreases significantly cell proliferation.Lidocaine (1-10 nM; 24-72 hours) inhibits cell viability and achieves the most suppressing effects at the concentration of 10 nM and treatment time 48 hours.Lidocaine (10 nM; 48 hours) increases significantly the apoptotic cell rate.Lidocaine (10 nM; 48 hours) down-regulates Cyclin D1 and up-regulates p21 expression significantly.(In Vivo):Lidocaine (Lignocaine) causes completely reversible tail nerve block in rats. Mechanical nociception block produced by lidocaine has slower onset and faster recovery compared with thermal nociception block.
  • In Vitro
    Lidocaine (Lignocaine) (10 nM; 48 hours) decreases significantly cell proliferation. Lidocaine (1-10 nM; 24-72 hours) inhibits cell viability and achieves the most suppressing effects at the concentration of 10?nM and treatment time 48?hours. Lidocaine (10 nM; 48 hours) increases significantly the apoptotic cell rate. Lidocaine (10 nM; 48 hours) down-regulates Cyclin D1 and up-regulates p21 expression significantly. Cell Proliferation Assay Cell Line:The human gastric cancer cell line MKN45 Concentration:10?nM Incubation Time:48 hours Result:Decreased significantly cell proliferation.Cell Viability Assay Cell Line:The human gastric cancer cell line MKN45 Concentration:1, 5 and 10?nMIncubation Time:24, 48, 72 hours Result:Inhibited MKN45 cell viability.Apoptosis Analysis Cell Line:The human gastric cancer cell line MKN45 Concentration:10?nM Incubation Time:48 hours Result:Increased significantly the apoptotic cell rate.Western Blot Analysis Cell Line:The human gastric cancer cell line MKN45 Concentration:10?nM Incubation Time:48 hours Result:Down-regulated Cyclin D1 and up-regulated p21 expression significantly.
  • In Vivo
    Lidocaine (Lignocaine) causes completely reversible tail nerve block in rats. Mechanical nociception block produced by lidocaine has slower onset and faster recovery compared with thermal nociception block.
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR| Sodium Channel
  • Research Area
    Cardiovascular Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    6108-05-0
  • Formula Weight
    288.82
  • Molecular Formula
    C14H22N2O·HCl·H2O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    O.Cl.CCN(CC)CC(=O)NC1=C(C)C=CC=C1C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Sheets PL, et al. J Physiol. 2007 Jun 15;581(Pt 3):1019-3
molnova catalog
related products
  • BLU-945

    BLU-945 is a reversible, potent, highly selective, and orally available epidermal growth factor receptor tyrosine kinase inhibitor (TKIs).

  • GSK-LSD1 dihydrochlo...

    GSK-LSD1 2HCl is a specificity irreversible LSD1 inhibitor (IC50: 16 nM). The selectivity of GSK-LSD1 for LSD1 is >1000 fold over other closely related FAD utilizing enzymes (i.e. MAO-A, LSD2, MAO-B).

  • AZD-3759

    A potent, oral active, BBB-penetrating EGFR inhibitor (IC50=7.2 nM, L858R pEGFR).